Duanbang Zhuanggan Junzhi Ji (短棒状杆菌制剂)短棒状杆菌制剂

This is a medicine registration record from NMPA data.本页为国家药监局药品注册记录。

Labeled sections from the recorded Chinese source are included below. English wording is a reference translation when one is on file, not an official English label.本记录未接入产品级适应症/安全性标注字段。

生产企业Manufacturer

主要成分Active Ingredients

药物知识说明

短棒状杆菌 系从健康人胸骨骨髓中分离 经培养 提纯是一种在国家药监局注册认定的药品。该药品含有相关活性成分。

该药品关联的活性成分包括:灭活Mie Huo、经培养Jingpei Yang。这些成分信息来自国家药监局数据库。

您可以探索含有相同成分的其他药品:灭活-33f96604成分药品。

本页面内容来自国家药监局数据库,MedicineGraph在此基础上提供关系图谱和知识导航。

Medicine Knowledge

This medicine (original name: 短棒状杆菌制剂) is a medicine registered with the national drug regulatory authority. It contains active ingredient(s) as recorded.

Active ingredients associated with this product: 灭活Mie Huo, 经培养Jingpei Yang.

Explore other medicines containing the same ingredient: 灭活 productsProducts containing this recorded ingredient.

Source: MedicineGraph authoritative database. Relationships derived from registered product information.

这是什么What is this

  • 通用名/品名Recorded product name: 短棒状杆菌制剂Recorded Chinese name: 短棒状杆菌制剂
  • 规格Specification: 2ml2 mL

本段仅展示注册/说明书已记录的身份属性,不含适应症或用法建议。Identity attributes from registration/leaflet records only; no indications or usage advice.

主要成分Ingredients

生产企业Manufacturer

  • 上海生物制品研究所Shanghai Shengwu Zhipin Yanjiu Suo

注册信息NMPA approval number

  • 批准文号NMPA approval number: 国药准字S10820181

关联实体Relationships

信息来源Source and scope

国家药品监督管理局(中国)药品注册数据及已接入说明书字段。National Medical Products Administration (China) medicine-registration data and linked leaflet fields.

  • 品名来源Name source: 10多万条药品说明书数据库 (HIGH)Package-insert database (more than 100,000 records) (HIGH)
  • 生产企业来源Manufacturer source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)

范围:当前 MedicineGraph 注册记录及已记录的精确关系;非完整目录,亦不构成疗效等同主张,也不支持换用判断。不含适应症/安全性推断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence. No inferred indications/safety.

本段为已核准说明书原文摘录(非改写、非AI摘要),非正式英文标签,亦不构成用药建议。 Not an official English label and not medical advice. English wording, when shown, is a reference translation of the Chinese source label.

English translation for reference. Translated from the Chinese source label. Not an official English label and not medical advice.

NMPA approval number

国药准字S10820181

Manufacturer

Chinese legal name: 上海生物制品研究所

Indications

English translation unavailable. The original Chinese source label remains available below.

Dosage and administration

English translation unavailable. The original Chinese source label remains available below.

Adverse reactions

English translation unavailable. The original Chinese source label remains available below.

Contraindications

English translation unavailable. The original Chinese source label remains available below.

Precautions

English translation unavailable. The original Chinese source label remains available below.

Storage

English translation unavailable. The original Chinese source label remains available below.

Specification

English translation unavailable. The original Chinese source label remains available below.

中文说明书原文Original Chinese source label

批准文号

国药准字S10820181

生产企业

上海生物制品研究所

适应症

主要用于癌性胸水,结合手术治疗早、中期肺癌。可配合常规治疗方法进行乳腺癌、鼻咽癌、晚期肺癌、黑色素瘤以及癌症的体表转移灶的治疗。本制剂对牛皮癣(银屑病)、再生障碍性贫血、女阴白斑、感染性哮喘等也有一定疗效。

用法用量

1.一般为皮下或肌内注射。腔内注射以氯化钠注射液进行适当稀释。瘤内或瘤周采用下述剂量,多点注射以减轻局部反应。|2.初次注射0.5~1.0ml,以后可酌情逐次增加0.5ml,直至2ml。肌内、腔内及多点注射可酌情增量,最多4.0ml(皮下不宜超过2.0ml)。|3.女阴白斑等可在患部涂抹,每日一次,每次1.0~2.0ml;如症状减轻,可根据需要,延长用药间隔。

不良反应

注射局部常有肿痛、硬结,持续约两周,有时出现一过性发热。胸腔注射可有一过性反应加重及发热,可对症处理。

禁忌

发热38℃以上,重症心血管病人,肝、肾功能异常者禁用。

注意事项

1.使用前检查包装容器。标签,外观,有效期是否符合要求。|2.治疗前后,宜作血、尿常规及免疫指标等检查,出现血、尿常规检查不正常或免疫指标持续下降者停用,注射当日勿过度疲劳。|3.用前须充分摇匀,有摇不散的凝块时勿用。

贮藏

密封,置阴凉处。

规格

2ml

证据Evidence

  • 批准文号: 国药准字S10820181
  • rights: 本段为已核准说明书原文摘录(非改写、非AI摘要),非正式英文标签,亦不构成用药建议。

信息来源Source and scope

国家药品监督管理局(中国)药品注册数据。National Medical Products Administration (China) medicine-registration data.

范围:当前 MedicineGraph 注册记录及已记录的精确关系;非完整目录,亦不构成疗效等同主张,也不支持换用判断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence.